Common and other GVHD manifestations according to the 2005 NIH-CC present in children at the time of initial onset of cGVHD
| NIH-CC cGVHD organ system and clinical manifestation* . | Frequency in all cGVHD cases (n = 51) . | Frequency in confirmed NIH-CC cGVHD cases (n = 43) . |
|---|---|---|
| Skin (n = 32; 62.7%) | ||
| Dry skin | 22 (43.1) | 19 (44.2) |
| Erythema/maculopapular rash | 17 (33.3) | 15 (34.9) |
| Pruritus | 13 (25.5) | 12 (27.9) |
| Isolated hyperpigmentation | 6 (11.8) | 6 (14) |
| Isolated hypopigmentation | 5 (9.8) | 5 (9.8) |
| Ichthyosis | 5 (9.8) | 4 (9.3) |
| Keratosis pilaris | 3 (5.9) | 2 (4.7) |
| GI tract (n = 20; 39.2%) | ||
| Anorexia | 18 (35.3) | 15 (34.9) |
| Weight loss/failure to thrive | 15 (29.4) | 13 (30.2) |
| Nausea/vomiting | 10 (19.6) | 7 (16.3) |
| Chronic diarrhea | 6 (11.8) | 5 (11.6) |
| Liver (n = 14; 27.5%) | ||
| Increased total bilirubin, alkaline phosphatase, AST, and/or ALT >2× ULN | 14 (27.5) | 13 (30.2) |
| Mouth (n = 16; 31.4%) | ||
| Erythema | 11 (21.6) | 10 (23.3) |
| Pain | 8 (15.7) | 7 (16.3) |
| Mucositis | 5 (9.8) | 5 (11.6) |
| Gingivitis | 1 (2) | 1 (2.3) |
| Eyes (n = 11; 21.6%) | ||
| Itchy | 9 (17.6) | 9 (20.9) |
| Photophobia | 3 (5.9) | 3 (7) |
| Blepharitis | 2 (4) | 2 (4.7) |
| Excessive tearing | 2 (4) | 2 (4.7) |
| Difficulty opening eyes in morning | 2 (4) | 2 (4.7) |
| Periorbital hyperpigmentation | 1 (2) | 1 (2.3) |
| Scalp (n = 6; 11.8%) | ||
| Thinning of scalp hair | 6 (11.8) | 6 (14) |
| Musculoskeletal system (n = 1; 5.9%) | ||
| Muscle weakness | 1 (2) | 1 (2.3) |
| Genital (n = 1; 5.9%) | ||
| Vaginal dryness | 1 (2) | 1 (2.3) |
| Other | ||
| Pericardial/pleural effusions/ascites | 4 (7.8) | 2 (4.7) |
| Eosinophilia | 3 (5.9) | 3 (7) |
| Immune thrombocytopenia | 1 (2) | 0 |
| Nephrotic syndrome | 1 (2) | 0 (0) |
| Cardiomyopathy | 1 (2) | 1 (2.3) |
| Neuropathy | 1 (2) | 1 (2.3) |
| NIH-CC cGVHD organ system and clinical manifestation* . | Frequency in all cGVHD cases (n = 51) . | Frequency in confirmed NIH-CC cGVHD cases (n = 43) . |
|---|---|---|
| Skin (n = 32; 62.7%) | ||
| Dry skin | 22 (43.1) | 19 (44.2) |
| Erythema/maculopapular rash | 17 (33.3) | 15 (34.9) |
| Pruritus | 13 (25.5) | 12 (27.9) |
| Isolated hyperpigmentation | 6 (11.8) | 6 (14) |
| Isolated hypopigmentation | 5 (9.8) | 5 (9.8) |
| Ichthyosis | 5 (9.8) | 4 (9.3) |
| Keratosis pilaris | 3 (5.9) | 2 (4.7) |
| GI tract (n = 20; 39.2%) | ||
| Anorexia | 18 (35.3) | 15 (34.9) |
| Weight loss/failure to thrive | 15 (29.4) | 13 (30.2) |
| Nausea/vomiting | 10 (19.6) | 7 (16.3) |
| Chronic diarrhea | 6 (11.8) | 5 (11.6) |
| Liver (n = 14; 27.5%) | ||
| Increased total bilirubin, alkaline phosphatase, AST, and/or ALT >2× ULN | 14 (27.5) | 13 (30.2) |
| Mouth (n = 16; 31.4%) | ||
| Erythema | 11 (21.6) | 10 (23.3) |
| Pain | 8 (15.7) | 7 (16.3) |
| Mucositis | 5 (9.8) | 5 (11.6) |
| Gingivitis | 1 (2) | 1 (2.3) |
| Eyes (n = 11; 21.6%) | ||
| Itchy | 9 (17.6) | 9 (20.9) |
| Photophobia | 3 (5.9) | 3 (7) |
| Blepharitis | 2 (4) | 2 (4.7) |
| Excessive tearing | 2 (4) | 2 (4.7) |
| Difficulty opening eyes in morning | 2 (4) | 2 (4.7) |
| Periorbital hyperpigmentation | 1 (2) | 1 (2.3) |
| Scalp (n = 6; 11.8%) | ||
| Thinning of scalp hair | 6 (11.8) | 6 (14) |
| Musculoskeletal system (n = 1; 5.9%) | ||
| Muscle weakness | 1 (2) | 1 (2.3) |
| Genital (n = 1; 5.9%) | ||
| Vaginal dryness | 1 (2) | 1 (2.3) |
| Other | ||
| Pericardial/pleural effusions/ascites | 4 (7.8) | 2 (4.7) |
| Eosinophilia | 3 (5.9) | 3 (7) |
| Immune thrombocytopenia | 1 (2) | 0 |
| Nephrotic syndrome | 1 (2) | 0 (0) |
| Cardiomyopathy | 1 (2) | 1 (2.3) |
| Neuropathy | 1 (2) | 1 (2.3) |
All data are n (%).
ALT, alanine aminotransferase; AST, aspartate aminotransferase; GI, gastrointestinal; ULN, upper limit normal.
Percentage shown by each organ system reflects the proportion of individuals with cGVHD (including all patients with NIH-CC or non–NIH-CC cGVHD) with ≥1 common or other cGVHD manifestation in that organ system at the time of initial cGVHD diagnosis. Common and other cGVHD manifestations as per 2005 NIH-CC that were not reported to the study (0 patients) are not included.